Pediatric Drugs

, Volume 5, Issue 10, pp 685–698 | Cite as

Treatment of Childhood Asthma

How Do the Available Options Compare?
Therapy In Practice

Abstract

The National Asthma Council of Australia suggests that “the aim of preventive therapy should be to enable patients to enjoy a normal life (comparable with that of non-asthmatic children), with the least amount of medication and at minimal risk of adverse events. The level of maintenance therapy should be determined by symptom control and lung function in the interval periods.” The British Thoracic Society/Scottish Intercollegiate Guidelines Network states that the aims of the pharmacological treatment of asthma should be to control symptoms, prevent exacerbations and achieve the best possible lung function with minimal adverse effects. We have used the current published international guidelines to highlight the international differences in management recommendations, and compared the possible pharmacological options with a focus on the above ideals.

Cromones have been used for many years in childhood asthma. Most evidence suggests they now have little role. Regarding inhaled corticosteroids (ICS), beclomethasone and budesonide are essentially similar in their efficacy. Fluticasone propionate is equally as effective at one-half the equivalent dose of budesonide or beclomethasone. Adverse effects are rare in dosages <400 μg/day of budesonide and beclomethasone or <200 μg/day of fluticasone propionate, but may occur in individual patients. Relevant clinical adverse effects are rare and pharmacological systemic effects are less noticeable with budesonide and fluticasone propionate than with beclomethasone, but data are conflicting. Long-acting β2-adrenoceptor agonists (β2-agonists) are recommended once low-dose ICS have failed to control symptoms. The main pharmacological difference between the agents is that formoterol is a full β2-adrenergic agonist, whereas salmeterol is a partial agonist at the β2-adrenoceptor and has a unique pharmacological action. The main clinical distinction between these two agents is that their onset of bronchodilation differs. Bronchodilation begins at about 3 minutes after inhalation of formoterol, which is similar to the short-acting agents, whereas salmeterol has a much slower onset of action at about 15–30 minutes. The many in vitro differences between the two drugs are probably not clinically relevant. There are no comparative pediatric data on the leukotriene modifiers to make clear recommendations.

Notes

Acknowledgements

Thanks to Dr Iolo Doull (Consultant Respiratory Paediatrician) University Hospital of Wales, for his advice on the growth and steroids section.

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    National Asthma Campaign (Australia). Asthma management handbook [online]. Available from URL: http://www.nationalasthma.org.au [Accessed 2002 Sep 4]
  2. 2.
    The British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003; 58Suppl. 1: i1–i94Google Scholar
  3. 3.
    Fish L, Lung CL, The Antileukotriene Working Group. Adherence to asthma therapy. Ann Allergy Asthma Immunol 2001; 86 6 Suppl. 1: 24–30PubMedCrossRefGoogle Scholar
  4. 4.
    Bender BG. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 2002; 109(6 Suppl.): S554–9PubMedCrossRefGoogle Scholar
  5. 5.
    Falliers CJ. Cromolyn sodium (disodium cromoglycate) prophylaxis. Pediatr Clin North Am 1975; 22(1): 141–8PubMedGoogle Scholar
  6. 6.
    Edwards AM, Stevens MT. The clinical efficacy of inhaled nedocromil sodium (Tilade) in the treatment of asthma. Eur Respir J 1993; 6: 35–41PubMedGoogle Scholar
  7. 7.
    Berman BA, Fenton MM, Girsch LS, et al. Cromolyn sodium in the treatment of children with severe, perennial asthma. Pediatrics 1975; 55(5): 621–9PubMedGoogle Scholar
  8. 8.
    Lenny W, Milner AD. Nebulised soidum cromoglycate in the preschool wheezy child. Arch Dis Child 1978; 53: 474–6CrossRefGoogle Scholar
  9. 9.
    Cogswell JJ, Simpkiss MJ. Nebulised sodium cromoglycate in recurrently wheezy preschool children. Arch Dis Child 1985; 60: 736–8PubMedCrossRefGoogle Scholar
  10. 10.
    Eigen H, Reid JJ, Dahl R, et al. Evaluation of the addition of cromolyn sodium to bronchodilator maintenance therapy in the long-term management of asthma. Clin Immunol 1987; 80: 612–21Google Scholar
  11. 11.
    Shapiro GG, Furukawa CT, Pierson WE, et al. Double-blind evaluation of nebulized cromolyn, terbutaline, and the combination for childhood asthma. J Allergy Clin Immunol 1988; 81: 449–54PubMedCrossRefGoogle Scholar
  12. 12.
    Edwards AM, Stevens MT. The clinical efficacy of inhaled nedocromil sodium (Tilade) in the treatment of asthma. Eur Respir J 1993; 6: 35–41PubMedGoogle Scholar
  13. 13.
    Carlsen KH, Larsson K. The efficacy of inhaled disodium cromoglycate and glucocorticoids. Clin Exp Allergy 1996; 26(4): 8–17PubMedCrossRefGoogle Scholar
  14. 14.
    Furfaro S, Spier S, Drblik SP, et al. Efficacy of cromoglycate in persistently wheezing infants. Arch Dis Child 1994; 71: 331–4PubMedCrossRefGoogle Scholar
  15. 15.
    Tasche MJA, van der Wouden JC, Uijen JHJM, et al. Randomised placebo-controlled trial of inhaled sodium cromoglycate in 1–4 year old children with moderate asthma. Lancet 1997; 350: 1060–4PubMedCrossRefGoogle Scholar
  16. 16.
    Tasche MJ, Uijen JH, Bernsen RM, et al. Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systematic review. Thorax 2000; 55(11): 913–20PubMedCrossRefGoogle Scholar
  17. 17.
    The British Thoracic Society, The National Asthma Campaign, The Royal College of Physicians of London, et al. The British guidelines on asthma management 1995 review and position statement. Thorax 1997; 52 Suppl. 1: S1–20Google Scholar
  18. 18.
    National Asthma Campaign 1998 (Australia). Asthma management handbook [online]. Available from URL: http://www.nationalasthma.org.au/ [Accessed 2003 Sep 4]
  19. 19.
    Alton EW, Kingsleigh-Smith DJ, Munkonge FM, et al. Asthma prophylaxis agents alter the function of an airway epithelial chloride channel. Am J Respir Cell Mol Biol 1996; 14: 380–7PubMedGoogle Scholar
  20. 20.
    Howarth PH, Durham SR, Lee TK, et al. Influence of albuterol, cromolyn sodium, ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am Rev Respir Dis 1985; 132: 986–92PubMedGoogle Scholar
  21. 21.
    Blumenthal MN, Selcow J, Spector S, et al. A multicenter evaluation of the clinical benefits of cromolyn sodium aerosol by metered dose inhaler in the treatment of asthma. J Allergy Clin Immunol 1988; 81: 681–7PubMedCrossRefGoogle Scholar
  22. 22.
    Selcow JE, Mendleson LM, Rosen JP. Clinical benefits of cromolyn sodium aerosol in the treatment of asthma in children. Ann Allergy 1989; 62: 195–9PubMedGoogle Scholar
  23. 23.
    Croce J, Negreiros EB, Mazzei JAM, et al. A double-blind placebo controlled comparison of sodium cromoglycate and ketotifen in the treatment of childhood asthma. Allergy 1995; 50: 524–7PubMedCrossRefGoogle Scholar
  24. 24.
    Swartz HJ, Blumenthal M, Brady R. A comparative study of the clinical efficacy of nedocromil sodium and placebo: how does cromolyn sodium compare as an active control treatment? Chest 1996; 109: 945–52CrossRefGoogle Scholar
  25. 25.
    Morton AR, Ogle SL, Fitch KD. Effects of nedocromil sodium, cromolyn sodium and a placebo in exercise induced asthma. Ann Allergy 1992; 68: 143–8PubMedGoogle Scholar
  26. 26.
    Comis A, Valletta EA, Sette L, et al. Comparison of nedocromil sodium and sodium cromoglycate administered by pressurised aerosol, with and without a spacer device in exercise induced asthma in children. Eur Respir J 1993; 6: 523–6PubMedGoogle Scholar
  27. 27.
    De Benedictis FM, Tuteri G, Pazzelli P, et al. Cromolyn versus nedocromil: duration of action in exercise induced asthma in children. J Allergy Clin Immunol 1995; 96: 510–4PubMedCrossRefGoogle Scholar
  28. 28.
    Del Bono L, Dente FL, Patalano FL. Protective effect of nedocromil sodium and sodium cromoglycate on bronchospasm induced by cold air. Eur J Respir Dis 1986; 69Suppl. 147: 269–70Google Scholar
  29. 29.
    Spooner CH, Saunders LD, Rowe BH. Nedocromil sodium for preventing exercise induced bronchoconstriction. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2002Google Scholar
  30. 30.
    Kelly K, Spooner CH, Rowe BH. Nedocromil sodium versus sodium cromoglycate for preventing exercise-induced bronchoconstriction in asthmatics. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2002Google Scholar
  31. 31.
    Dawood AG, Hendry AT, Walker SR. The combined use of betamethasone valerate and sodium cromoglycate in the treatment of asthma. Clin Allergy 1971; 7: 161–5Google Scholar
  32. 32.
    Toogood JH, Jennings B, Lefcoe NM. A clinical trail of combined cromolyn/beclomethasone treatment for chronic asthma. J Allergy Clin Immunol 1981; 67(4): 317–24PubMedCrossRefGoogle Scholar
  33. 33.
    Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000; 343(15): 1113–4Google Scholar
  34. 34.
    Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticoster-oid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373–81PubMedCrossRefGoogle Scholar
  35. 35.
    Helms PJ. Inhaled disodium cromoglycate as maintenance therapy for childhood asthma: time to consign to history? Thorax 2000; 55: 886PubMedCrossRefGoogle Scholar
  36. 36.
    Barnes PJ. Current issues for establishing inhaled corticosteroids as the anti-inflammatory agents of choice in asthma. J Allergy Clin Immunol 1998; 101: S427–33PubMedCrossRefGoogle Scholar
  37. 37.
    Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868–75PubMedCrossRefGoogle Scholar
  38. 38.
    Bisgaard H, Pedersen S. Safety of treatment [of asthma]. Eur Respir J 1996; 9(21): 28–34SGoogle Scholar
  39. 39.
    Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmaco-dynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998; 101: S440–6PubMedCrossRefGoogle Scholar
  40. 40.
    Kelly HK. Establishing a therapeutic index for inhaled corticosteroids (part 1): pharmacokinetic/pharmacodynamic comparison of the inhaled steroids. J Allergy Clin Immunol 1998; 102: S36–51PubMedCrossRefGoogle Scholar
  41. 41.
    Haahtela T. The long-term influence of therapeutic interventions in asthma with emphasis on inhaled steroids and early disease. Clin Exp Allergy 1998; 28Suppl. 5: 133–40PubMedCrossRefGoogle Scholar
  42. 42.
    van Essen-Zandvilet EE, Hughes MD, Waalkens HJ, et al. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992; 146: 547–54Google Scholar
  43. 43.
    Sears MR. Growing up with asthma. BMJ 1994; 309: 72–3PubMedCrossRefGoogle Scholar
  44. 44.
    National Institutes of Health. Global initiative for asthma: global strategy for asthma management and prevention. Bethesda (MD): NIH, 2002. NHLBI/WHO workshop report, 02-3659.Google Scholar
  45. 45.
    Moller C, Stromberg L, Oldaeus G, et al. Efficacy of once daily versus twice-daily administration of budesonide by Turbohaler in children with stable asthma. Pediatr Pulmonol 1999; 28: 337–43PubMedCrossRefGoogle Scholar
  46. 46.
    Heuck C, Wolthers OD, Kollerup G, et al. Adverse effects of inhaled Budesonide (800 micrograms) on growth and collagen turnover in children with asthma: a double blind comparison of once-daily versus twice-daily administration. J Pediatr 1998; 133(5): 608–12PubMedCrossRefGoogle Scholar
  47. 47.
    Brogden RN, Heel RC, Speight TM, et al. Beclomethasone dipropionate: a reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis. Drugs 1984; 28(2): 99–126PubMedCrossRefGoogle Scholar
  48. 48.
    Vathenen AS, Knox AJ, Wisniewski A, et al. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 1991; 143: 1317–21PubMedGoogle Scholar
  49. 49.
    Bjorkander J, Formgren N, Johansson SA, et al. Methodological aspects of clinical trials with inhaled corticosteroids: results of two comparisons between two steroid aerosols in patients with asthma. Eur J Respir Dis 1982; 63Suppl. 122: 108–17Google Scholar
  50. 50.
    Ebden P, Jenkins A, Houston G, et al. Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (1500μgs/day) and budesonide (1600μgs/day), for chronic asthma. Thorax 1986; 41: 869–74PubMedCrossRefGoogle Scholar
  51. 51.
    Springer C, Avital A, Maayan CH, et al. Comparison of budesonide and beclomethasone dipropionate for treatment of asthma. Arch Dis Child 1987; 62: 815–9PubMedCrossRefGoogle Scholar
  52. 52.
    Baker JW, Mellon M, Wald J, et al. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 1999; 103(2): 414–21PubMedCrossRefGoogle Scholar
  53. 53.
    Onhoj J, Thorsson L, Bisgaard H. Lung deposition of inhaled drugs increases with age. Am J Respir Crit Care Med 2000; 162(5): 1819–22PubMedGoogle Scholar
  54. 54.
    Adams N, Bestall J, Jones PW. Budesonide for chronic asthma in children and adults. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2003Google Scholar
  55. 55.
    Katz Y, Lebas FX, Medley HV, et al. Fluticasone propionate 50 micrograms BID versus 100 micrograms BID in the treatment of children with persistent asthma. Fluticasone Propionate Study Group. Clin Ther 1998; 20(3): 424–37PubMedCrossRefGoogle Scholar
  56. 56.
    Bisgaard H, Gillies J, Groenewald M, et al. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. Am J Respir Crit Care Med 1999; 160(1): 126–3PubMedGoogle Scholar
  57. 57.
    Ferguson AC, Spier S, Manjra A, et al. Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. J Pediatr 1999; 134(4): 422–7PubMedCrossRefGoogle Scholar
  58. 58.
    Barnes NC, Hallett C, Harris T. Clinical experience with fluticasone propionate in asthma; a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med 1998; 92(1): 95–104PubMedCrossRefGoogle Scholar
  59. 59.
    Brown PH, Blundell G, Greening AP, et al. Do large volume spacer devices reduce the systemic effects of high doses inhaled corticosteroids? Thorax 1990; 45: 736–9PubMedCrossRefGoogle Scholar
  60. 60.
    Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax 1991; 46(12): 891–4PubMedCrossRefGoogle Scholar
  61. 61.
    Brown PH, Greening AP, Crompton GK. Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function. Thorax 1993; 48: 233–8PubMedCrossRefGoogle Scholar
  62. 62.
    Fitzgerald D, Van Asperen P, Mellis C, et al. Fluticasone propionate 750 micrograms/day versus beclomethasone dipropionate 1500 micrograms/day: comparison of efficacy and adrenal function in paediatric asthma. Thorax 1998; 53: 656–61PubMedCrossRefGoogle Scholar
  63. 63.
    Lipworth BJ. Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship. Pulm Pharmacol 1996; 9(1): 19–27PubMedCrossRefGoogle Scholar
  64. 64.
    Drake AJ, Howells RJ, Shield JP, et al. Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate. BMJ 2002; 32: 1081–2CrossRefGoogle Scholar
  65. 65.
    Holt S, Suder A, Weatherall M, et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001; 323: 253–6PubMedCrossRefGoogle Scholar
  66. 66.
    Hyams JS, Carey DE. Corticosteroids and growth. J Pediatr 1998; 113: 249–54Google Scholar
  67. 67.
    Russell G. Asthma and growth. Arch Dis Child 1993; 69(6): 695–8PubMedCrossRefGoogle Scholar
  68. 68.
    Bisgaard H. Use of inhaled corticosteroids in pediatric asthma. Pediatr Pulmonol Suppl 1997; 15: 27–33PubMedCrossRefGoogle Scholar
  69. 69.
    Konig P. Inhaled corticosteroids: their present and future role in the management of asthma. J Allergy Clin Immunol 1988; 82(2): 297–306PubMedCrossRefGoogle Scholar
  70. 70.
    Shaw NJ, Fraser NC, Weller PH. Asthma treatment and growth. Arch Dis Child 1997; 77(4): 284–6PubMedCrossRefGoogle Scholar
  71. 71.
    Martin AJ, Landau LI, Phelan PD. The effect on growth of childhood asthma. Acta Paediatr Scand 1981; 70: 683–8PubMedCrossRefGoogle Scholar
  72. 72.
    Simons FE. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997; 337: 1659–65PubMedCrossRefGoogle Scholar
  73. 73.
    Verberne AA, Frost C, Roorda RJ, et al. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Group. Am J Respir Crit Care Med 1997; 156: 688–95PubMedGoogle Scholar
  74. 74.
    Wolthers OD, Pedersen S. Short term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate. Arch Dis Child 1993; 68: 673–6PubMedCrossRefGoogle Scholar
  75. 75.
    MacKenzie CA, Wales JK. Growth of asthmatic children. BMJ 1991; 303: 163–5CrossRefGoogle Scholar
  76. 76.
    Wolthers OD, Pedersen S. Controlled study of linear growth in asthma in asthmatic children with inhaled glucocorticosteroids. Pediatrics 1992; 89: 839–42PubMedGoogle Scholar
  77. 77.
    Agertoft L, Pedersen S. Short term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study. Eur Respir J 1997; 10: 1507–12PubMedCrossRefGoogle Scholar
  78. 78.
    Tinkelman DG, Reed CE, Nelson HS, et al. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of choice, mild to moderately severe asthma in children. Pediatrics 1993; 92: 64–77PubMedGoogle Scholar
  79. 79.
    Doull IJM, Freezer NJ, Holgate ST. Growth of prepubertal with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995; 151:1715–9PubMedGoogle Scholar
  80. 80.
    Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma. Pediatrics 2000; 106(1): E8PubMedCrossRefGoogle Scholar
  81. 81.
    The Childhood Asthma Management Program Research Group. Long term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343: 1054–63CrossRefGoogle Scholar
  82. 82.
    Allen DB, Bronsky EA, LaForce CF, et al. Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group. J Pediatr 1998; 132: 472–7PubMedCrossRefGoogle Scholar
  83. 83.
    Price JF. Inhaled corticosteroids: clinical relevance of safety measures. Pediatr Pulmonol 1997; 15: 40–5CrossRefGoogle Scholar
  84. 84.
    Rao R, Gregson RK, Jones AC, et al. Systemic effects of inhaled corticosteroids on growth and bone turnover in children with asthma: a comparison of fluticasone and beclamethasone. Eur Respir J 1990; 13: 87–94Google Scholar
  85. 85.
    Price JF, Russell G, Hinmarsh PC, et al. Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Pediatr Pulmonol 1997; 24: 178–86PubMedCrossRefGoogle Scholar
  86. 86.
    Doull IJM, Campbell MJ, Holgate ST. Duration of growth suppressive effects of regular inhaled corticosteroids. Arch Dis Child 1997; 78: 172–3CrossRefGoogle Scholar
  87. 87.
    Agertoft L, Pederson S. Effect of long term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343: 1064–9PubMedCrossRefGoogle Scholar
  88. 88.
    Allen DB, Wolthers OD. Inhaled corticosteroids, growth, and compliance [letter]. N Engl J Med 2002; 347: 1210–1PubMedGoogle Scholar
  89. 89.
    Balfour-Lynn L. Growth and childhood asthma. Arch Dis Child 1986; 61: 1049–55PubMedCrossRefGoogle Scholar
  90. 90.
    Silverstein MD, Yunginger JW, Reed CE, et al. Attained adult height after childhood asthma: effect of glucocorticoids therapy. J Allergy Clin Immunol 1997; 99: 466–74PubMedCrossRefGoogle Scholar
  91. 91.
    Van Bever HP, Desager KN, Lijssens N, et al. Does treatment of asthmatic children with inhaled corticosteroids affect their adult height? Pediatr Pulmonol 1999; 27: 369–75PubMedCrossRefGoogle Scholar
  92. 92.
    Wolthers OD, Riis BJ, Pedersen S. Bone turnover in asthmatic children treated with oral prednisolone or inhaled budesonide. Pediatr Pulmonol 1993; 16(6): 341–6PubMedCrossRefGoogle Scholar
  93. 93.
    Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclo-methasone. Eur Respir J 1998; 12: 1346–53PubMedCrossRefGoogle Scholar
  94. 94.
    Pedersen S, Warner J, Wahn U, et al. Growth, systemic safety and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open label, randomized comparison of extra fine and conventional aerosols in children. Pediatrics 2002; 109(6): E92–102PubMedCrossRefGoogle Scholar
  95. 95.
    Wales JK, Barnes ND, Swift PG. Growth retardation in children on steroids for asthma [letter]. Lancet 1991; 338(8781): 1535PubMedCrossRefGoogle Scholar
  96. 96.
    Eid N, Morton R, Olds B, et al. Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate. Pediatrics 2002; 109(2): 217–21PubMedCrossRefGoogle Scholar
  97. 97.
    Rabinovitch N, Gelfand EW. New approaches to the treatment of childhood asthma. Curr Opin Pediatr 1998; 10(3): 243–9PubMedCrossRefGoogle Scholar
  98. 98.
    Akpinarli A, Tuncer A, Saraclar Y, et al. Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial. Arch Dis Child 1999; 81(1): 45–8PubMedCrossRefGoogle Scholar
  99. 99.
    Johnson M. Pharmacology of long-acting beta agonists. Ann Allergy Asthma Immunol 1995; 75: 177–9PubMedGoogle Scholar
  100. 100.
    Verberne AAPH, Hop WCJ, Creyghton FBM, et al. Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma. J Allergy Clin Immunol 1996; 97: 938–46PubMedCrossRefGoogle Scholar
  101. 101.
    Meijer GG, Postma DS, Mulder PGH, et al. Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. Am J Respir Crit Care Med 1995; 152: 1887–92PubMedGoogle Scholar
  102. 102.
    Lipworth BJ. Airway subsensitivity with long-acting beta-2 agonists. Drug Saf 1997; 16: 295–308PubMedCrossRefGoogle Scholar
  103. 103.
    Kips JC, Pauwels RA. Long acting inhaled β2 agonist therapy in asthma. Am J Respir Crit Care Med 2001; 164: 923–32PubMedGoogle Scholar
  104. 104.
    Miller-Larson A, Persdotter S, Jerre A, et al. Formoterol is more effective than salmeterol in the inhibition of human eosinophil superoxide production induced by conditioned medium from bronchial epithelial cells [abstract]. Am J Respir Crit Care Med 2001; 159: A591Google Scholar
  105. 105.
    Verberne AAPH, Hop WCJ, Kerrebijn KF. Effect of a single dose of inhaled salmeterol on baseline airway caliber and methacholine-induced airway obstruction in asthmatic children. J Allergy Clin Immunol 1993; 91: 51–8CrossRefGoogle Scholar
  106. 106.
    Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticoster-oid. Lancet 1994; 344(8917): 219–24PubMedCrossRefGoogle Scholar
  107. 107.
    Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of inhaled salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 152(5): 1481–8Google Scholar
  108. 108.
    Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337(20): 1405–11PubMedCrossRefGoogle Scholar
  109. 109.
    Verberne AA, Frost C, Duiverman EJ, et al. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. Am J Respir Crit Care Med 1998; 158: 213–9PubMedGoogle Scholar
  110. 110.
    Green CP, Price JF. Prevention of exercise induced asthma by inhaled salmeterol xinafoate. Arch Dis Child 1992; 67(8): 1014–7PubMedCrossRefGoogle Scholar
  111. 111.
    Nelson HS, Berkowitz RB, Tinkelman DA, et al. Lack of sub sensitivity to albuterol after treatment with salmeterol in patients with asthma. Am J Respir Crit Care Med 1999; 159 (5 Pt 1): 1556–61PubMedGoogle Scholar
  112. 112.
    Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997; 99: 655–9PubMedCrossRefGoogle Scholar
  113. 113.
    Gleeson JG, Loftus BG, Price JF. Placebo controlled trial of systemic corticosteroids in acute childhood asthma. Acta Paediatr Scand 1990; 79: 1052–8PubMedCrossRefGoogle Scholar
  114. 114.
    Langton HS, Hewer S, Reid F, et al. Prednisolone in acute childhood asthma: clinical responses to three doses. Respir Med 1998; 92(3): 541–6CrossRefGoogle Scholar
  115. 115.
    Rowe BH, Spooner CH, Ducharme FM, et al. Corticosteroids for preventing relapse following acute exacerbations of asthma. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Software, 2002Google Scholar
  116. 116.
    Rose EA, Schwartz K. Is a 2-day course of oral dexamethasone more effective than 5 days of oral prednisone in improving symptoms and preventing relapse in children with acute asthma [letter]? J Fam Pract 2001; 50(11): 993PubMedGoogle Scholar
  117. 117.
    Horowitz L, Zafrir O, Gilboa S, et al. Acute asthma: single dose oral steroids in pediatric community clinics. Eur J Pediatr 1994; 153(7): 526–30PubMedCrossRefGoogle Scholar
  118. 118.
    Wolthers OD, Pedersen S. Short term linear growth in asthmatic children during treatment with prednisolone. BMJ 1990; 301: 145–8PubMedCrossRefGoogle Scholar
  119. 119.
    Allen DB, Mullen ML, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994; 93: 967–76PubMedCrossRefGoogle Scholar
  120. 120.
    Andersson P, Brange C, Sonmark B, et al. Anti-anaphylactic and anti-inflammatory effects of xanthines of xanthines in the lung. In: Andersson KE, Persson CGA, editors. Anti-asthma xanthines and adenosine. Amsterdam: Excerpta Medica, 1985: 187–92Google Scholar
  121. 121.
    Sullivan P, Beclir S, Jaffar Z, et al. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994; 343: 1006–8PubMedCrossRefGoogle Scholar
  122. 122.
    Barnes PJ, Pauwels RA. Theophylline in the management of asthma: time for reappraisal? Eur Respir J 1994; 7(3): 579–91PubMedCrossRefGoogle Scholar
  123. 123.
    Szefler SJ, Bender BG, Jusko WJ, et al. Evolving role of theophylline for treatment of chronic childhood asthma. J Pediatr 1995; 127(2): 176–85PubMedCrossRefGoogle Scholar
  124. 124.
    Kidney J, Dominguez M, Taylor PM, et al. Immunomodulation by theophylline in asthma: demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995; 151(6): 1907–14PubMedGoogle Scholar
  125. 125.
    Scordamaglia A, Ciprandi G, Ruffoni S, et al. Theophylline and the immune response: in vitro and in vivo effects. Clin Immunol Immunopathol 1988; 48: 238–46PubMedCrossRefGoogle Scholar
  126. 126.
    Joad J, Ahrens RC, Lindgren SD, et al. Extrapulmonary effects of maintenance therapy with theophylline and inhaled albuterol in patients with chronic asthma. J Allergy Clin Immunol 1986; 78: 1147–53PubMedCrossRefGoogle Scholar
  127. 127.
    Joad J, Ahrens RC, Lindgren SD, et al. Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma. J Allergy Clin Immunol 1987; 79: 78–85PubMedCrossRefGoogle Scholar
  128. 128.
    Bender BG, Ikle DN, DuHamel T, et al. Neuropsychological and behavioural changes in asthmatic children treated with beclomethasone dipropionate versus theophylline. Pediatrics 1998; 101(3): 355–60PubMedCrossRefGoogle Scholar
  129. 129.
    Nassif EG, Weinberger M, Thompson R, et al. The value of maintenance theophylline in steroid-dependent asthma. N Engl J Med 1981; 303: 71–5CrossRefGoogle Scholar
  130. 130.
    Hendeles L, Weinberger M, Szefler S, et al. Safety and efficacy of theophylline in children with asthma. J Pediatr 1992; 120 (2 Pt 1): 177–83PubMedCrossRefGoogle Scholar
  131. 131.
    Rachelefsky G, Wo J, Adelson J, et al. Behaviour abnormalities and poor school performance due to oral theophylline use. Pediatrics 1986; 78: 1133–8PubMedGoogle Scholar
  132. 132.
    Springer C, Goldenberg B, Ben Dov I, et al. Clinical, physiologic, and psychologic comparison of treatment by cromolyn or theophylline in childhood asthma. J Allergy Clin Immunol 1985; 76: 64–9PubMedCrossRefGoogle Scholar
  133. 133.
    Holgate S. Mediator and cytokine mechanisms in asthma. Thorax 1993; 48: 103–9PubMedCrossRefGoogle Scholar
  134. 134.
    Drazen JM. Asthma therapy with agents preventing leukotriene synthesis or action. Proc Assoc Am Physicians 1999; 111(6): 547–59PubMedCrossRefGoogle Scholar
  135. 135.
    Henderson WR. The role of leukotrienes in inflammation. Ann Intern Med 1994; 121: 684–97PubMedGoogle Scholar
  136. 136.
    Ducharme FM. Antileukotriene as add on therapy to inhaled glucocorticoids in patients with asthma: systemic review of current evidence. BMJ 2002; 324: 1545PubMedCrossRefGoogle Scholar
  137. 137.
    Ducharme FM, Hicks GC. Anti-leukotriene agents compared to inhaled cortico-steroids in the management of recurrent and/or chronic asthma. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Software, 2002Google Scholar
  138. 138.
    Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 2001; 138(5): 694–8PubMedCrossRefGoogle Scholar
  139. 139.
    Israel E, Dermarkarian R, Rosenberg M, et al. The effects of 5-lipoxygenase inhibitor on asthma induced by dry cold air. N Engl J Med 1990; 323: 1740–4PubMedCrossRefGoogle Scholar
  140. 140.
    Meltzer SS, Hasday JD, Cohn J, et al. Inhibition of exercise induced bronchospasm by zileuton; a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996; 53: 931–5Google Scholar
  141. 141.
    Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119: 1059–66PubMedGoogle Scholar
  142. 142.
    Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA 1996; 275: 931–6PubMedCrossRefGoogle Scholar
  143. 143.
    Liu MC, Dube LM, Lancaster J, et al. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trail. J Allergy Clin Immunol 1996; 98: 859–71PubMedCrossRefGoogle Scholar
  144. 144.
    Makker HK, Lau LC, Thomson HW, et al. The protective effect of inhaled leukotriene D4 antagonist ICI 204,219 against exercise induced asthma. Am Rev Respir Dis 1993; 147: 1413–8PubMedGoogle Scholar
  145. 145.
    Pearlman DS, Ostrom NK, Bronsky EA, et al. The leukotriene D4-receptor antagonist zafirlukast attenuates exercise induced bronchospasm in children. J Pediatr 1999; 134: 273–9PubMedCrossRefGoogle Scholar
  146. 146.
    Spector SL, Smith LJ, Glass M, et al. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 antagonist, in subjects with bronchial asthma. Am Rev Respir Crit Care Med 1994; 150: 618–23Google Scholar
  147. 147.
    Lofdhal C-G, Reiss F, Leff JA, et al. Randomised placebo controlled trial of effect of leukotriene antagonist, monteleukast, on tapering of inhaled steroids in asthmatic patients. BMJ 1999; 319: 87–90CrossRefGoogle Scholar
  148. 148.
    Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral monteleukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Ann Intern Med 1999; 130: 487–95PubMedGoogle Scholar
  149. 149.
    Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol with oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103: 1075–80PubMedCrossRefGoogle Scholar
  150. 150.
    Knorr B, Franchi LM, Bisgaard H, et al. Monteleukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108(3): E48PubMedCrossRefGoogle Scholar
  151. 151.
    Franco J, Artes MJ. Pulmonary eosinophilia associated with montelucast. Thorax 1999; 54: 558–60PubMedCrossRefGoogle Scholar
  152. 152.
    Tang M, Powell CVE. Childhood asthma as an allergic disease: rationale for the development of future treatment. Eur J Pediatr 2001; 160: 696–704PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Mercy HospitalCorkRepublic of Ireland
  2. 2.Department of PaediatricsUniversity Hospital of Wales, Heath HospitalCardiffUK

Personalised recommendations